Annual Drug Patent Expirations for SUNLENCA
Sunlenca is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from one supplier. There are four patents protecting this drug.
This drug has one hundred and forty-seven patent family members in forty-five countries.
The generic ingredient in SUNLENCA is lenacapavir sodium. One supplier is listed for this compound. Additional details are available on the lenacapavir sodium profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com